NCT06922591: An ongoing trial by Tango Therapeutics, Inc.
This trial is ongoing. It must report results 2 years, 6 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06922591 |
|---|---|
| Title | A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic Cancer With MTAP Loss and Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 31, 2025 |
| Completion date | June 30, 2027 |
| Required reporting date | June 29, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |